Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial.

Authors :: Zeidan AM
Qi CZ
Yang H
Garnham A
Shah MV
Pandya BJ
Source :: Leukemia & lymphoma [Leuk Lymphoma] 2022 Mar; Vol. 63 (3), pp. 762-764. Date of Electronic Publication: 2021 Nov 08.
Publication Year :: 2022

Subjects :: Aniline Compounds therapeutic use
Humans
Mutation
Salvage Therapy
fms-Like Tyrosine Kinase 3 genetics
Leukemia, Myeloid, Acute drug therapy
Leukemia, Myeloid, Acute genetics
Pyrazines therapeutic use

Full Text Access

Tools